Literature DB >> 3262681

Relative inefficiency of terminal complement activation.

S Bhakdi1, W Fassbender, F Hugo, M P Carreno, C Berstecher, P Malasit, M D Kazatchkine.   

Abstract

The efficiency of generation of fluid-phase SC5b-9 and membrane C5b-9(m) complexes relative to cleavage of C3 and C5 was studied. Fluid-phase C activation was induced through addition of purified bacterial Ag to human serum. Sephadex beads were used as particulate activators of the alternative pathway. Rabbit or antibody-coated sheep or human E were used to study formation of cytolytic C5b-9(m) complexes. The molar ratios of C3a:C5a generated in the model systems were found to be in the range of 60 to 200:1 in the case of soluble immune complex activators, and 70 to 150:1 with particulate activators and cells. The efficiency of C5 cleavage relative to C3 cleavage increased on surfaces with the density of antibody and/or C3b-binding sites. With soluble immune complexes, the efficiency of subsequent SC5b-9 generation displayed wide variations dependent on Ag and donor with molar ratios of C5a:SC5b-9 ranging from 30:1 for teichoic acid and sometimes approaching 1:1 for streptolysin-O. In contrast, activation on particles or cells always led to C5a:C5b-9 (calculated as the sum of generated moles SC5b-9 and C5b-9(m] ratios approaching 1:1. Hence, there is an overall inefficiency of terminal sequence activation in the C cascade due first to a dissociation at the level of C5 convertase formation/C5-cleavage and second, to a frequent inefficiency of C5b-utilization in the fluid-phase. The results provide an explanation for the very low levels of SC5b-9 found in plasma of healthy individuals and in patients with C-consuming immune complex disease.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3262681

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  Complement activation and bioincompatibility. The terminal complement complex for evaluation and surface modification with heparin for improvement of biomaterials.

Authors:  T E Mollnes; V Videm; J Riesenfeld; P Garred; J L Svennevig; E Fosse; K Hogasen; M Harboe
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

2.  Activation of complement during apheresis.

Authors:  G Hetland; T E Mollnes; P Garred
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

3.  Circulating complement proteins in patients with sepsis or systemic inflammatory response syndrome.

Authors:  S Stöve; T Welte; T O Wagner; A Kola; A Klos; W Bautsch; J Köhl
Journal:  Clin Diagn Lab Immunol       Date:  1996-03

Review 4.  Functions and relevance of the terminal complement sequence.

Authors:  S Bhakdi; F Hugo; J Tranum-Jensen
Journal:  Blut       Date:  1990-06

5.  Microparticles provide a novel biomarker to predict severe clinical outcomes of dengue virus infection.

Authors:  Nuntaya Punyadee; Dumrong Mairiang; Somchai Thiemmeca; Chulaluk Komoltri; Wirichada Pan-Ngum; Nusara Chomanee; Komgrid Charngkaew; Nattaya Tangthawornchaikul; Wannee Limpitikul; Sirijitt Vasanawathana; Prida Malasit; Panisadee Avirutnan
Journal:  J Virol       Date:  2014-11-19       Impact factor: 5.103

6.  Complement-mediated serum sensitivity among spirochetes that cause Lyme disease.

Authors:  A P van Dam; A Oei; R Jaspars; C Fijen; B Wilske; L Spanjaard; J Dankert
Journal:  Infect Immun       Date:  1997-04       Impact factor: 3.441

7.  Tubing loops as a model for cardiopulmonary bypass circuits: both the biomaterial and the blood-gas phase interfaces induce complement activation in an in vitro model.

Authors:  J Gong; R Larsson; K N Ekdahl; T E Mollnes; U Nilsson; B Nilsson
Journal:  J Clin Immunol       Date:  1996-07       Impact factor: 8.317

Review 8.  Alpha-toxin of Staphylococcus aureus.

Authors:  S Bhakdi; J Tranum-Jensen
Journal:  Microbiol Rev       Date:  1991-12

9.  In vivo clearance studies of the terminal fluid-phase complement complex in rabbits.

Authors:  F Hugo; C Berstecher; S Krämer; W Fassbender; S Bhakdi
Journal:  Clin Exp Immunol       Date:  1989-07       Impact factor: 4.330

10.  Complement activation in septic baboons detected by neoepitope-specific assays for C3b/iC3b/C3c, C5a and the terminal C5b-9 complement complex (TCC).

Authors:  T E Mollnes; H Redl; K Høgåsen; A Bengtsson; P Garred; L Speilberg; T Lea; M Oppermann; O Götze; G Schlag
Journal:  Clin Exp Immunol       Date:  1993-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.